Ibritumomab Tiuxetan is a radioimmunotherapy pharmaceutical product consisting of a murine monoclonal antibody directed against the CD20 antigen and a tiuxetan chelating component that enables radiometal attachment. When radiolabeled with yttrium-90, it forms an antibody-based therapeutic agent designed to deliver targeted radiation to CD20-positive B cells.
Ibritumomab Tiuxetan is used in selected patients with CD20-positive B-cell non-Hodgkin lymphoma, according to approved indications and applicable regulatory requirements.
Ibritumomab Tiuxetan is a complex biological and radiopharmaceutical-related pharmaceutical ingredient requiring specialized manufacturing, purification, conjugation and analytical characterization.
Unlike conventional small-molecule APIs, its quality assessment requires control of antibody identity, protein purity, aggregation, conjugation characteristics, immunoreactivity and other biologic attributes. For the radiolabeled product, additional controls apply to radionuclide identity, radiochemical purity and radioactive concentration.
CAS Number: 359861-75-9
Molecule Type: Monoclonal Antibody–Chelator Conjugate
Target: CD20
Drug Class: Radioimmunotherapy Agent
Pharmacological Class: CD20-Directed Monoclonal Antibody
Therapeutic Class: Antineoplastic / Radioimmunotherapeutic Agent
Therapeutic Area: Oncology / Hematology
Ibritumomab binds specifically to the CD20 antigen expressed on the surface of B lymphocytes.
After attachment to CD20-positive cells, the antibody-associated radionuclide can deliver localized beta radiation to malignant and neighboring B cells. This targeted radiation contributes to destruction of CD20-positive malignant cells.
The therapeutic product uses yttrium-90 (Y-90) as the therapeutic radionuclide. A related imaging component may use indium-111 (In-111) where applicable to the product protocol.
Ibritumomab Tiuxetan is used in selected treatment settings involving:
Specific indications depend on the approved product labeling and regulatory jurisdiction.
Ibritumomab Tiuxetan represents a targeted radioimmunotherapy approach that combines:
Monoclonal antibody targeting + radionuclide delivery + localized radiation
The antibody provides biological targeting through CD20 recognition, while the attached radionuclide delivers cytotoxic radiation to targeted cells.
Tiuxetan is a chelating component used to bind the radionuclide to the antibody conjugate. This enables the formation of a stable antibody-radionuclide complex suitable for radioimmunotherapeutic applications.
Manufacturing of Ibritumomab Tiuxetan involves specialized biological and conjugation processes that may include:
Radiolabeling operations require specialized facilities, validated procedures and appropriate radiation-safety controls.
Quality evaluation may include:
For the radiolabeled product, additional testing may include:
The antibody-conjugate drug substance should be stored according to its validated stability conditions and approved product specification. Radiolabeled material requires additional controls related to radionuclide decay, radiation safety and validated handling procedures.
Ibritumomab Tiuxetan is relevant to pharmaceutical research involving CD20-targeted therapy, monoclonal antibodies, radioimmunotherapy, targeted radiation delivery and B-cell malignancies.
Ibritumomab Tiuxetan is a CD20-directed monoclonal antibody–chelator conjugate used as the antibody component of a targeted radioimmunotherapy approach. When radiolabeled with yttrium-90, it delivers beta radiation to CD20-positive B cells and is used in selected patients with B-cell non-Hodgkin lymphoma.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 5.0 – 7.0 |
| Individual Impurity | ≤ 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |